Cloud Pharmaceuticals is a holding company of venture assets. Each drug program that reaches IND is placed in its own LLC for further funding. In addition, the company holds minority and majority stakes in various healthcare technology ventures.
Drug Product Pipeline Our leading drug development programs are: - mRNA vaccine for Pancreatic Cancer [expected to enter the clinic in 2022] - repurposed personalized medicine "cocktail" drug for hypertension [expected to enter the clinic in 2022] - reformulated and novel EP3 inhibitor for Thrombosis [expected to enter the clinic in 2022] - peptide drug targeting monoclonal antibody B6 for a wide range of Coronaviruses [preclinical] - peptide for chemotherapy side effect reduction to disrupt beta-CR [late stage preclinical] - novel Jak3 inhibitor for topical Dermatitis [preclinical] - PD-1 inhibitor for immuno-oncology [discovery] - PDKK2 inhibitor for rare disease [discovery]
Technology Holdings Our technology ventures and venture partners are: - minority investment in PolarisQB, a quantum computing molecular design venture - majority investment in AI Hub, a tele-health monitoring venture - joint venture with Pocket Doctor and Drug Logic for precision medicine